BRISTOL-MYERS SQUIBB COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.96 USD | -0.08% |
|
-0.92% | -13.80% |
| 02:00pm | Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators | MT |
| 01:51pm | Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 46.02B | Sales 2025 * | 46.16B | Capitalization | 89.17B |
|---|---|---|---|---|---|
| Net income 2024 * | -5.4B | Net income 2025 * | 10.22B | EV / Sales 2024 * | 2.79 x |
| Net Debt 2024 * | 39.2B | Net Debt 2025 * | 31.85B | EV / Sales 2025 * | 2.62 x |
| P/E ratio 2024 * |
-16.8
x | P/E ratio 2025 * |
8.31
x | Employees | 34,100 |
| Yield 2024 * |
5.47% | Yield 2025 * |
5.74% | Free-Float | 69.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bristol-Myers Squibb Company
More recommendations
More press releases
More news
| 1 day | +1.22% | ||
| 1 week | -1.92% | ||
| Current month | +0.11% | ||
| 1 month | -14.28% | ||
| 3 months | -8.32% | ||
| 6 months | -16.72% | ||
| Current year | -14.27% |
1 week
43.33
44.76
1 month
43.3351.68
Current year
43.3355.04
1 year
43.3369.10
3 years
43.3381.44
5 years
42.4881.44
10 years
42.4881.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 215 M€ | +10.80% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 18 M€ | +3.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 44.05 | +0.14% | 2 307 414 |
| 24-05-03 | 43.99 | +0.66% | 12,104,489 |
| 24-05-02 | 43.7 | -1.15% | 15,962,587 |
| 24-05-01 | 44.21 | +0.61% | 13,247,159 |
| 24-04-30 | 43.94 | -1.57% | 17,715,997 |
Delayed Quote Nyse, May 03, 2024 at 04:00 pm EDT
More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
43.99
USD
Average target price
53.19
USD
Spread / Average Target
+20.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.27% | 89.17B | |
| +26.08% | 662B | |
| +21.62% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 289B | |
| +13.68% | 234B | |
| +4.61% | 198B | |
| -10.59% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- BMY Stock